Células madre

SMO-IN-2 is a SMO inhibitor with antiproliferative activity and anticancer activity and inhibits Hh signaling.SMO-IN-2 can be used in the study of cancer.

Crenigacestat (LY3039478) is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most of the tumor cell lines tested.

VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.

CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.

Silmitasertib (CX-4945) is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki: 0.38 nM).

KenPaullone (9-Bromopaullone), a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation.

SWTX-143, a novel covalent inhibitor, specifically and irreversibly binds to the palmitoylation pocket of all four TEAD isoforms, inhibiting the transcriptional

20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo).

gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.

IWP-4 (Inhibitor of Wnt Production-4) is a potent Wnt inhibitor.

ML116 is a potent and selective STAT3 inhibitor.

Cardiogenol C hydrochloride (Cardiogenol C) can induces the differentiation of ESCs into cardiomyocytes (EC50= 100 nM).

TNIK-IN-7 is a Traf2 and Nck interacting kinase (TNIK) inhibitor with antitumor activity for the study of signaling and proliferation in colorectal cancer cells

Tankyrase-IN-2 is a selective, potent and orally active inhibitor of tankyrase with IC50s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively

Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat Cys-C. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat Cys-C. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat Cys-C, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.

JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].

BML-286 is a WNT pathway modulator with potential anticancer activity and induces β-catenin- and TCF- dependent transcriptional activity.

JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.

Elezanumab (ABT-555) is a human anti-RGMa antibody blocking BMP signaling via SMAD1/5/8; IC50 ~97 pM. It aids neuroregeneration and repairs neuronal damage.